Barry Shin
About Barry Shin
Barry Shin is the Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Trevena, with a strong background in investment banking and corporate advisory in the biopharmaceutical sector.
Barry Shin's Role at Trevena
Barry Shin holds prominent positions at Trevena, serving as the Executive Vice President, Chief Operating Officer, and Chief Financial Officer. He initially joined the company in June 2019 as Senior Vice President and Chief Financial Officer. In February 2024, he was promoted to his current roles, reflecting his significant contribution and leadership within the company. In these roles, Shin oversees financial strategies, operational management, and executive decision-making processes.
Barry Shin's Career in Investment Banking
Barry Shin boasts over 17 years of experience in investment banking and corporate advisory, with a particular focus on the biopharmaceutical sector. Before joining Trevena, he was Managing Director in the Healthcare Investment Banking Group at Mizuho Securities. From 2012 to 2017, he served as Managing Director at Guggenheim Securities’ Healthcare Investment Banking Group. Earlier in his career, Shin held progressive roles at Piper Jaffray from 2005 to 2012. His extensive background includes advising numerous biopharmaceutical companies on merger and acquisition (M&A) and financing transactions.
Barry Shin's Early Career and Legal Experience
Before his tenure in investment banking, Barry Shin began his career as a corporate attorney. From 2001 to 2005, he advised healthcare and technology companies on financing and M&A transactions. This legal experience provided him with a foundational understanding of corporate structures, legal frameworks, and transactional processes, which he later applied to his work in investment banking and corporate advisory.
Barry Shin's Educational Background
Barry Shin earned a Bachelor of Science (B.Sc.) degree and a joint Juris Doctor (J.D.) and Master of Business Administration (M.B.A.) degree from the University of Toronto. His comprehensive education combined legal, scientific, and business studies, equipping him with a diverse skill set essential for his roles in investment banking, corporate advisory, and executive management within the biopharmaceutical industry.